Semaglutide
Dyspnea
University of California, Los Angelesprotein_peptidePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Dyspnea cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Liraglutide University of California, Los Angeles | Phase 4 | BB |
Orlistat University of California, Los Angeles | Phase 4 | BB |
Tirzepatide University of California, Los Angeles | Phase 4 | BB |
Same molecule, other indications
Semaglutide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →